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ABSTRACT 36 
Background: Clarity and accuracy of the pharmacy aspects of cancer clinical trial protocols is 37 
essential. Inconsistencies and ambiguities in such protocols have the potential to delay research and 38 
jeopardize both patient safety and collection of credible data. The Chemotherapy and Pharmacy 39 
Advisory Service (CPAS) was established by the UK National Cancer Research Network (NCRN), 40 
currently known as National Institute for Health Research Clinical Research Network (NIHR 41 
CRN), to improve the quality of pharmacy-related content in cancer clinical research protocols. This 42 
paper reports the scope of CPAS, its methodology of mandated protocol review and pharmacy-related 43 
guidance initiatives, and its current impact. 44 
Methods: Over a 6-year period (2008-2013) since the inception of CPAS, cancer clinical trial 45 
protocols were reviewed by the service, prior to implementation at clinical trial sites. A customised 46 
Review Checklist was developed and used by a panel of experts to standardise the review process, and 47 
report back queries and inconsistencies to chief investigators. Based on common queries, a Standard 48 
Protocol Template comprising specific guidance on drug-related content and a Pharmacy Manual 49 
Template were developed. In addition, a guidance framework was established to address ‘ad hoc’ 50 
pharmacy-related queries. 51 
The most common remarks made at protocol review have been summarized and categorized through 52 
retrospective analysis. In order to evaluate the impact of the service, chief investigators were asked to 53 
respond to queries made at protocol review and make appropriate changes to their protocols. 54 
Responses from chief investigators have been collated and acceptance rates determined. 55 
Results: A total of 176 protocols were reviewed. The median number of remarks per protocol was 26 56 
of which 20 were deemed clinically relevant, and mainly concerned the drug regimen, support 57 
medication, frequency and type of monitoring, and drug supply aspects. Further analysis revealed that 58 
62% of chief investigators responded to the review. All responses were positive with an overall 59 
acceptance rate of 89% of the proposed protocol changes. 60 
Conclusion: Review of pharmacy content of cancer clinical trial protocols is feasible and exposes 61 
many undetected clinically relevant issues that could hinder efficient trial conduct. Our service audit 62 
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revealed that the majority of suggestions were effectively incorporated in the final protocols. The 63 
refinement of existing, and development of new pharmacy-related guidance documents by CPAS 64 
might aid in better and safer clinical research. 65 
  66 
KEY WORDS: chemotherapy, pharmacy aspects, cancer, clinical trials, quality control 67 
68 
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INTRODUCTION 69 
Approximately 14 million adults worldwide were diagnosed with cancer in 2012, 8.2 million 70 
of them died because of the disease. In the United Kingdom (UK) 396 per 100 000 people 71 
were confronted with a cancer diagnosis in that same year. It is estimated that the incidence of 72 
cancer will increase another 55% and 35% for men and women, respectively, between 2007 73 
and 2030 due to growth and ageing of the population.1, 2 At present, the cancer research UK 74 
website, which aims to list all cancer trials and studies recruiting in the UK, registered 1884 75 
trials, a number that is more likely to increase rather than decrease in the near future.3  76 
The success of a clinical trial largely depends on the quality of its protocol.4 Incompleteness, 77 
inconsistencies or errors in a protocol may impact the proper conduct of a trial with 78 
subsequent risk to patient safety and ultimately accuracy of results. As a response to the 79 
inadequacy of current research protocols, Chan et al. recently published guidance in the form 80 
of a checklist of recommended items to include in a clinical intervention trial protocol, though 81 
it did not include pharmacy-related content.5 The latter is, however, an essential part of any 82 
clinical trial involving investigational medicinal products. Moreover, it is especially important 83 
in cancer trials, where the drugs used may be cytotoxic and/or form part of a complex 84 
treatment regimen involving multiple drugs, administered in particular orders over a number 85 
of days and frequencies.  86 
Some pharmacists had the impression that poor study design and poor pharmacy content in 87 
protocols was creating a substantial workload and hindering the set up and running of clinical 88 
trials. Delays were being caused by issues including choice of inappropriate infusion 89 
solutions, inappropriate volumes for infusion of cytotoxic doses, enforced use of 90 
inappropriate packaging and labelling of drug supplies, and complicated funding and 91 
purchasing arrangements agreed between the pharmaceutical companies and the trial 92 
organizing bodies.6 In the past, oncology pharmacists also frequently reported organizational 93 
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issues and inconsistencies in clinical trials, often related to various protocol interpretations 94 
due to differences in hospital local practices. Some of these inconsistencies may have put 95 
patients at unnecessary risk of errors, increased the workload for pharmacy and nursing staff, 96 
as well as jeopardized accuracy of the trial outcome.  97 
The rising number of cancer clinical trials, the more stringent national and international 98 
legislation and Good Manufacturing Practice requirements, combined with the increasing 99 
demand for pharmacy support prompted the National Cancer Research Network (NCRN; 100 
currently known as National Institute for Health Research Clinical Research Network (NIHR 101 
CRN)) to form a standardisation committee in 2003, which evolved into the current 102 
Chemotherapy and Pharmacy Advisory Service (CPAS) by the end of 2007.7, 8  103 
It was set up to advise chief investigators, clinical trials units and clinical studies groups on 104 
the chemotherapy- and pharmacy-related content of their protocols, in order to maintain and 105 
enhance research quality and thereby aid development of high-quality research protocols. The 106 
aim was firstly to involve pharmacists, clinicians, nurses and pharmacy technicians at the 107 
early stages of protocol design to address problems with the protocol and underpin the ability 108 
of hospital pharmacies to support clinical trials of new and established drugs. Secondly, it was 109 
intended that through a transparent cycle of continuous improvement and feedback, the 110 
learning from the service would eventually mean that it was no longer required.  111 
Currently, CPAS constitutes a multidisciplinary national team of pharmacists, research 112 
nurses, haematologist and oncologists. It has a formal remit to: (1) consider trials to be 113 
adopted by the NIHR CRN and review draft protocols, (2) provide support to investigators 114 
and others about medicine-related issues in oncology/haematology trials, (3) review published 115 
evidence to help standardise chemotherapy administration in clinical trials (e.g. addressing 116 
generic issues such as dosage modifications in organ dysfunction, calculations of body 117 
surface area, modifications for obesity, etc.). CPAS reviews are mandatory for all new drug 118 
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trials approved by the Cancer Research UK Clinical Trials Awards and Advisory Committee 119 
and the National Institute for Health Research Health Technology Assessment programme. 120 
The mandatory process does not involve Medical Research Council funded trials and 121 
industry-funded studies but they can be submitted for review on a voluntary basis. 122 
This paper describes the establishment of the service, its methodology, the retrospective 123 
review of its activities for the first six years (from January 2008 until December 2013) and 124 
analysis of the responses from chief investigators to issues raised at review. 125 
 126 
METHODS 127 
CPAS: the organisation 128 
The CPAS core comprises four ex officio members, or non-reviewers, namely the chair, the 129 
representatives of respectively the NIHR CRN and National Cancer Research Institute 130 
(NCRI) clinical studies group secretariat, and an NIHR CRN pharmacy advisor. The latter 131 
serves as the main point of contact and liaison between researchers and CPAS, and 132 
coordinates CPAS activities and the advisory service as a whole.  At present, CPAS 133 
membership includes 50 Panel and 15 Committee members, consisting of 37 pharmacists, 13 134 
clinicians, 5 research nurses, 5 pharmacy technicians, 1 clinical trials unit manager, and the 135 
four core Committee members. All CPAS non-core members are responsible for protocol 136 
reviewing and other protocol- or pharmacy-related queries. The Committee members also 137 
fulfil a strategic decision-making role.  138 
 139 
Review of draft protocols 140 
A Review Checklist was developed based on a literature review on clinical drug research 141 
guidelines, medication errors in cancer chemotherapy, and common pharmacy-related issues. 142 
The checklist was developed to standardise the conduct of reviews by the CPAS panel of 143 
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experts, and was used to report back queries and inconsistencies to chief investigators. The 144 
current checklist consists of 12 sections with a total of 119 questions (Supplementary Online 145 
Appendix 1).9 The sections include: (1) regimen (nomenclature, etc.), (2) support medication, 146 
(3) dose calculation, (4) inclusion/exclusion criteria, (5) randomisation, (6) monitoring, (7) 147 
dose modification/delay, (8) drug information/concomitant medication, (9) drug 148 
administration, (10) drug supplies, (11) drug accountability/drug returns and (12) general. The 149 
first 11 categories are considered to be of clinical significance whilst the 12th category pools 150 
comments that are related to the general formatting and grammar, trial administration or 151 
financial issues. Reviewers are encouraged to add any relevant comments not covered by the 152 
standard checklist. 153 
A draft protocol can be submitted for review at any point after funding approval, once the 154 
drug treatment section of the protocol is near completion, but no later than two months prior 155 
to multi-centre research ethics committee submission (Figure 1). Initially, a minimum of 156 
three reviewers, of which at least one was an oncology pharmacist, reviewed each protocol in 157 
parallel. Currently, the number of reviewers for each protocol averages five, namely one 158 
clinician, a research nurse, and three pharmacists with different subspecialties. Reviewers are 159 
given two to three weeks turn-around time. The pharmacy advisor receives, collates and edits 160 
all final reviews into one anonymised document and returns it to the respective chief 161 
investigator within four to six weeks of submission. Whether or not the recommendations are 162 
incorporated into the final protocol remains at the chief investigator’s discretion. 163 
 164 
Support to investigators about medicine- and pharmacy-related content  165 
In addition to its review activity, CPAS provides pharmacy-related support, either by direct 166 
contact or through guidance documents to assist protocol writing. First, a Standard Protocol 167 
Template, detailing specific ‘Guidance on the drug-related content of clinical trial protocols’ 168 
9 
 
 
was created based on the aforementioned Review Checklist and finalised in 2008.10 It is 169 
subdivided into 8 sections: (1) trial procedures, (2) treatment of patients, (3) trial drugs, (4) 170 
glossary of formulae, (5) suggested capecitabine dose banding table, (6) manipulation of 171 
investigational medicinal products in the pharmacy, (7) labelling of investigational medicinal 172 
products and (8) note on oral anti-cancer therapy. It provides useful examples of phrases that 173 
could be incorporated in a protocol. A copy of the document can be found as the 174 
Supplementary Online Appendix 2, or on the website of the NIHR CRN.10  175 
Second, in June 2009, a Pharmacy Manual Template was created for guidance to investigators 176 
with the content of pharmacy manuals for clinical trials.11 It contains the following sections: 177 
(1) contact details of sponsor, (2) trial synopsis, (3) study medication, (4) randomisation, (5) 178 
prescribing, (6) dispensing, (7) accountability forms, (8) patient returns, (9) destruction, (10) 179 
hazards and (11) forms/templates. All documents are available online for use by others via the 180 
NIHR CRN website, or in the Supplementary Online Appendix 3. Last, as a unique group 181 
of national ‘experts’, CPAS, are available to answer ‘ad hoc’ questions addressing pharmacy-182 
related queries, or requests for advice, in relation to National Institute for Health Research 183 
portfolio studies. The queries range from specific study-related questions to general trial-184 
related questions (e.g. use of electronic prescribing system, patient randomisation faxes, 185 
transportation of refrigerated IMPs between hospital and satellite unit), and can be submitted 186 
to the pharmacy advisor. The pharmacy advisor considers the incoming queries and contacts 187 
relevant members of the CPAS panel for comment and advice. The comments are then 188 
collated  into a final anonymised response based on consensus opinion. Where opinion varies, 189 
the different viewpoints and suggestions are discussed and a best practice approach is agreed.  190 
All  queries and responses are  stored  for reference. This initiative has highlighted frequently 191 
posed questions which, for example, in March 2012 led to publication of an online 192 
investigational medicinal product statement12 defining which drugs in a clinical trial protocol, 193 
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are classified as investigational medicinal products and which are non investigational 194 
medicinal products. 195 
  196 
Retrospective analysis of protocol reviews 197 
All protocol review reports returned to the chief investigators for the 6-year period between 198 
the 1st of January 2008 and the 31th of December 2013, were analysed retrospectively. A 199 
detailed list of all of the 176 protocols reviewed can be found on the CPAS page of the NIHR 200 
CRN website and in the Supplementary Online Appendix 4.13 Trial characteristics were 201 
collected, and remarks that were retained in the final review report were summarized and 202 
categorized according to the twelve subsections of the Review Checklist described earlier. 203 
 204 
Evaluation survey 205 
At the time of receiving the final collated review for their protocol, a request was made to all 206 
chief investigators (i.e. those submitting their draft protocol for review) to provide feedback. 207 
They were asked to state whether or not they agreed with the issues raised at review and 208 
provide confirmation of changes made to their protocol as a result. A service evaluation audit 209 
was conducted to check chief investigator response rates and acceptance rates (% of remarks 210 
raised at review that were accepted and reflected in changes to the protocol) of proposed 211 
changes. This was done for all protocols reviewed in this 6-year period. 212 
 213 
Statistical Analysis 214 
Descriptive statistics were performed to present trial characteristics, frequency and type of 215 
remarks and response and acceptance rates. A response rate of 60% is considered as an 216 
acceptable level of response rate to surveys.14 All analyses were conducted using Microsoft® 217 
11 
 
 
Excel 2011 (Microsoft Inc., Redmond, WA) and IBM SPSS v.19 (SPSS Inc.®, Chicago, IL) 218 
software.  219 
 220 
RESULTS 221 
Protocols reviewed by CPAS and findings 222 
Trial characteristics of the 176 protocols that were reviewed, are described in Table 1. The 223 
median number of protocols per year reviewed was 27 (range 25 - 42) and appears to be 224 
stable over the years. Of these 4% were phase I trials, 51% were phase II trials, 25% were 225 
phase III trials, 1% were phase IV trials and 18% were combined phase I/II or II/III trials. The 226 
average time between submission of the protocol to CPAS and the return of the collated 227 
review was 35 days. This figure fluctuates between 21 days (and in one or two exceptional 228 
cases an excess of 80 days), depending on how busy CPAS service becomes at any one time. 229 
The disease categories subdivided according to the respective clinical specialty groups are 230 
listed in Table 1. The included experimental treatment modalities concerned mainly cytotoxic 231 
chemotherapy (24%), molecular targeted therapy (24%) or a combination of drugs (36%). 232 
About 9% concerned studies of drug combinations with radiotherapy, 2% anti-hormonal 233 
treatment and 1% immunotherapy.  234 
The review findings according to the 12 categories in the Protocol Review Checklist and the 235 
relative frequencies that each issue has arisen in the respective protocols are summarised in 236 
Figure 2a and 2b. The median number of remarks per protocol was 26 of which 20 were 237 
deemed clinically relevant. In our experience, the nature of the comments raised by reviewers 238 
fell into two broad categories: missing information and insufficient clarity of the information 239 
or guidance provided. The majority of clinically relevant remarks concerned the regimen 240 
(median [Q1,Q3]; 3 [1,6]), support medication (2 [1,4]), monitoring (2 [1,3]) and drug supply 241 
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aspects (2 [1,4]), and were the same over the years (Figure 2a). Some typical examples are 242 
listed in Table 2.  243 
 244 
Service evaluation survey 245 
A service evaluation survey was systematically sent to the respective chief investigators of 246 
which 62% responded. All responses were positive (qualitative responses; data not shown) 247 
which was reflected in a median overall acceptance rate of 89% of the by CPAS proposed 248 
protocol changes. Response rates and acceptance rates seemed to remain stable over the 249 
respective years (data not shown). 250 
 251 
DISCUSSION 252 
Cancer prevalence is high and will only increase in the near future. The quality of research 253 
protocols, in particular the pharmacy-related content, is of utmost importance to ensure cost-254 
efficient, timely and safe research. To the best of our knowledge, an initiative like CPAS is 255 
unique, and such activities that aim to support chief investigators improve the pharmacy-256 
related quality of cancer clinical trial protocols have not been published earlier. This paper 257 
describes the development of CPAS and reviews its activities from 2008 until 2013. The aim 258 
of CPAS is to raise awareness of the type, frequency and consequences of research protocol 259 
inadequacies, and to provide support to investigators either directly or in the form of guidance 260 
documents to assist the development of high quality clinical trial protocols.  261 
CPAS was established in response to a general perception by our research community that 262 
pharmacy departments were a barrier to starting and running clinical trials especially those 263 
involving complex chemotherapy regimens. It was not the intention of pharmacy departments 264 
to hinder research and within our pharmacy community it was recognised that the workload 265 
generated by inadequate pharmacy information within protocols often caused resource issues 266 
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and subsequent delays to research.15 A number of issues were raised that hindered trial 267 
implementation at the local level and which caused delays and problems in areas such as dose 268 
adjustments, dose capping, missing pharmacy information, supply of drugs and safe 269 
administration of chemotherapy.6 Local practice often differs between hospitals causing 270 
inconsistent or wrong interpretation, which can negatively affect trial conduct and 271 
consequently data accuracy. Moreover, any missing or unclear protocol information has the 272 
potential to adversely affect patient safety. The remit of CPAS is, therefore, to resolve these 273 
issues at the draft protocol stage and achieve consistency across the clinical trial portfolio 274 
hosted by the NIHR CRN.  275 
Qualitative evaluation of the CPAS review process, through the service evaluation survey, 276 
presented positive feedback. Indeed, the majority of investigators provided a written response 277 
to the final collated review, reporting that it was a helpful and constructive process that, in 278 
their opinion, reduced the number of protocol amendments that were required during the trial. 279 
The effectiveness of the service was also demonstrated by the remarkably high acceptance 280 
rate of the remarks raised by CPAS. The chief investigators accepted almost 9 out of 10 281 
proposed amendments, which underscores the relevance of CPAS. While CPAS activities 282 
have been appreciated by the chief investigators of cancer clinical drug trials, the cost-benefit 283 
of this time-extensive review process is not verifiable at present. Future research could, 284 
therefore, prospectively examine whether an upfront pharmacy review process reduces the 285 
number of required pharmacy-related amendments, treatment-related protocol violations, or 286 
the percentage of treatment-related hospitalisations or deaths. Moreover, future work to 287 
inspect the characteristics of clinical drug trials where the chief investigators did not respond 288 
to review comments or incorporate suggested changes could identify areas of further guidance 289 
or educational resource that CPAS could provide. Retrospective analysis did, at present, not 290 
reveal any differences in trial phase, clinical specialty group or type of investigational therapy 291 
14 
 
 
between cooperative and non-cooperative chief investigators (data not shown). The latter 292 
might have been reluctant to wait for CPAS feedback, since it is recognised that the turn-293 
around time for CPAS review and final collation could be seen as an addition of a substantial 294 
amount of time to an already lengthy protocol development period. As such, CPAS suggests 295 
that draft protocols are submitted as soon as possible and the review is conducted in parallel 296 
with other protocol development processes. Currently, the number of reviewers determined to 297 
scrutinise a draft protocol for CPAS is chosen to give a range of experience, specialities and 298 
views from different regions in the UK. It is possible that future refinements to the Review 299 
Checklist and elaboration on the detail of guidance documents already provided, might reduce 300 
the number of reviewers required and/or  the time period of the review process. 301 
Our systematic retrospective analysis indicated that a median of 26 remarks were suggested 302 
per protocol, and that the majority of remarks addressed by the reviewers were deemed 303 
clinically relevant. To our knowledge, this is the first time that such information, based on the 304 
use of a customised Review Checklist, is available. A formal request for more information 305 
about the protocol review process was sent to several cancer cooperative networks, however, 306 
only reciprocated by the National Cancer Institute and the Swiss Group for Clinical Cancer 307 
Research. Industry-funded trials or trials executed within a large cooperative group often 308 
provide in-house protocol review by scientific disease-specific committees, not always 309 
incorporating a pharmacist. However, there is only limited or no transparency regarding the 310 
protocol review process, and it thus serves to no benefit to external (academic) investigators. 311 
Our results indicate that the most frequently observed inconsistencies concerned the drug 312 
regimen, support medication, monitoring and drug supply aspects, thus highlighting the 313 
importance of collaboration between the oncology physician and clinical pharmacist at time 314 
of protocol design. CPAS protocol review included trial protocols of all phases, an extensive 315 
number of clinical specialty groups and a wide variety of cancer treatments. Results might, 316 
15 
 
 
however, not be extrapolable to commercially-funded trials. Future prospective research, 317 
addressing trials sponsored by industry and different funding agencies, might be useful to 318 
explore the potential for differences in protocol quality. 319 
Over the years that CPAS has been operating, the number of review remarks per protocol 320 
appears to have remained stable. This fact could indicate that CPAS is unlikely to become 321 
redundant in the future. On the other hand, it could also suggest that CPAS guidance 322 
documents and checklists are not well-known by investigators and the CPAS advisory 323 
function not well utilised. There are many factors involved in determining why an 324 
organisation does not learn from previous experience and these could be explored by CPAS to 325 
maximise their effectiveness. Sensitisation of other cooperative groups in oncology and other 326 
medical subspecialties might also be required to ensure a more wide-spread implementation 327 
of CPAS knowledge in the future. Continuous service evaluation audits and evaluation of the 328 
activities will no doubt lead to further service improvements and adaption of CPAS tools. 329 
Moreover, with growth the number of activities performed by CPAS may also further expand 330 
to include advice on practical clinical trial issues relevant to pharmacists, such as dose-331 
banding, chemotherapy stability and compatibility issues, and the incidence and avoidance of 332 
chemotherapy medication errors.  333 
In conclusion, we have described the development and activities of CPAS. Systematic 334 
analysis of mandated reviews of pharmacy-related aspects of cancer clinical trial protocols 335 
proved to be useful and improved the quality of the clinical trials hosted by the NIHR CRN. 336 
Moreover, with the refinement of previously published CPAS guidance, development of new 337 
CPAS guidance and lessons learned from the review process itself, we hope that this paper 338 
will lead to a more wide-spread implementation of our knowledge by other academic groups 339 
and better, safer clinical research. 340 
 341 
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Figure 2a. Number of remarks per review category per protocol 428 
 429 
 430 
 431 
 432 
Figure 2b. Relative frequency of remarks per review category presented as a pie chart. 433 
 434 
 435 
436 
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Table 1. Characteristics of the clinical trials reviewed between 2008 and 2013 437 
 Studies (N= 176) 
Characteristic No. % 
Year of Review   
2008 29 16 
2009 26 15 
2010 28 16 
2011 42 24 
2012 25 14 
2013 26 15 
   
Type of trial   
Phase I 7 4 
Phase I/II 19 11 
Phase II 90 51 
Phase II/III 13 7 
Phase III 44 25 
Phase IV 1 1 
Other 2 1 
   
Clinical Specialty Group   
Biomarkers & Imaging 
0 0 
Bladder (including penile) 9 5 
Brain 11 6 
Breast 16 9 
Children’s Cancer and 
Leukaemia 
3 2 
Colorectal 14 9 
Gynaecological 16 9 
Haematological Oncology 26 15 
Head and Neck 6 3 
Lung 10 6 
Lymphoma 13 7 
Melanoma 7 4 
Palliative and Supportive Care 1 1 
Primary Care 
0 0 
Prostate 8 5 
Psychosocial Oncology 
0 0 
Renal (including adrenal) 7 4 
Sarcoma 8 5 
Teenage and Young Adults 
0 0 
Testis 2 1 
Upper Gastro-Intestinal 
(including pancreas and liver) 
10 6 
Combined 9 5 
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Type of investigational 
Therapy 
  
Cytotoxic chemotherapy 43 24 
Hormonal therapy 3 2 
Molecular targeted therapy 42 24 
Immunotherapy 1 1 
Combination of drugs 63 36 
Combination with 
Radiotherapy  
15 9 
Other 9 5 
23 
 
 
Table 2. Examples of common relevant findings 438 
Regimen 
• No information on which drugs are IMPs and therefore which need accountability 
• Information missing on infusion times, stability of a product, diluents, use of non-PVC 
infusion bags and giving sets 
• Information missing on what to do if a patient vomits following a dose or misses a 
dose 
• Use of brand names instead of generic  
• Use of drug names that are not used in the UK e.g. acetaminophen instead of 
paracetamol 
• Information copied from previous protocol resulting in incorrect information being 
stated 
Support medication 
• No advice given for supportive medicines e.g. pre-meds, anti-emetics, hydration etc 
• 2mg/L Magnesium sulphate and 20mmol post-hydration bags insisted on by protocol 
(2mg/L = 0.008mmol Magnesium per litre) 
Dose calculation 
• No information on frequency of re-calculation of BSA or formula to use, re-
calculation of GFR and method of GFR calculation 
• No reference to dose banding 
• Dose banding table of chemotherapy with doses expected to be measured to 2 decimal 
places 
Monitoring 
• Information missing on haematological and biochemical monitoring  
• Different cut-offs specified in different areas of the protocol for discontinuing a drug 
due to renal  impairment 
• Screening investigations specified to be carried out within 14 days of treatment. 
Schedule of events table did not make this clear 
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Drug administration 
• Incorrect description of drug administration 
• Different drug preparation available, incorrect choice made for route of administration 
required 
• Proposed drug administration is not feasible in the specific study population 
 439 
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